News | SPECT Imaging | July 25, 2016

UltraSPECT Xpress3.Cardiac Installed at Four RWJPE Locations

Wide-beam reconstruction technology increases patient safety and comfort, reduces nuclear radiation doses and shortens scan times

UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise

July 25, 2016 — UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-based physician group in Central New Jersey, implemented UltraSPECT’s Xpress3.Cardiac solution at four of their sites. The sites include: Cardiology Associates of New Brunswick in New Brunswick, N.J.; Heart Specialists of Edison in Edison, N.J.; and New Brunswick Cardiology Group in their offices in Somerset and Monroe, N.J. 

The software will benefit patient safety by reducing the dosage of injected radiopharmaceuticals, while lowering the radiation exposure for patients and nuclear staff alike. In addition, the technology saves valuable time for patients and staff, as it can produce the same high-quality single photon emission computed tomography (SPECT) images in less time than is typically required during standard exams.

“The image quality and clarity are remarkably good with UltraSPECT, which is particularly impressive when you consider that our scan time has been reduced by half in 80-90 percent of the cases,” said Jose Torres, technology director, New Brunswick Cardiology Group, Somerset, N.J. “UltraSPECT also helped us eliminate the two-day study protocol for heavier patients, who used to have to come back the next day for a stress test because the shorter scan times allow us to do more in the same visit. Patients are also more comfortable during the scan because they have to lay still for a shorter period of time.”

Torres also notes that the radiation exposure numbers on staff’s monthly dosimetry reports have been steadily going down after the UltraSPECT implementation. This is due to both reduced scan time and reduced doses needed for imaging tests.

All four installations are part of RWJPE’s radiopharmaceutical supply agreement with Nuclear Diagnostic Products (NDP). NDP delivers high-quality diagnostic and therapeutic radiopharmaceuticals to its customers and offers UltraSPECT products to facilities looking for a cost-effective solution to achieve faster and safer imaging while enhancing their diagnostic capabilities.

For more information: www.ultraspect.com

Related Content

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topics at the conference. #ASNC #ASNC19 #ASNC2019

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topic at the conference.

Feature | Nuclear Imaging | November 22, 2019 | Dave Fornell, Editor
There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September...
Videos | Nuclear Imaging | November 07, 2019
American Society of Nuclear Cardiology (ASNC) President Rob Beanlands, M.D., shares a couple trends he sees in cardiac...
Videos | Nuclear Imaging | November 06, 2019
Doctor Robert Hendel explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at...
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. The image shows how SPECT allows the reader to distinguish between blood pool activity and radiotracer uptake.

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

Feature | Nuclear Imaging | July 22, 2019 | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS
Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the de
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Videos | Nuclear Imaging | August 21, 2018
Rami Doukky, M.D., professor of medicine, preventive medicine and radiology, and chief of the Division of Cardiology
ASNC Announces Keynote Speakers for 2018 Annual Scientific Session
News | Nuclear Imaging | August 08, 2018
August 8, 2018 — The American Society of Nuclear Cardiology’s (ASNC) Annual Scientific Session, ASNC2018, will kick o
Overlay Init